CDKL5 Current Knowledge, Gaps and Future Directions

Clinical Features

What is currently known¹

- CDD is a severe Developmental Epileptic Encephalopathy with onset in early infancy (A, B, C).
- Seizures are refractory although there may be an early honeymoon period in just under a half (B, C).
- Multiple seizure types, often with multiple phases, occur including epileptic spasms, tonic, myoclonic and generalised tonic-clonic seizures (B).
- Gross motor, fine motor and communication skills are all severely impaired with only a quarter of females able to take independent steps with males, if non-mosaic, even more impaired (B, C).
- Cerebral visual impairment (CVI) is present in at least three quarters of patients, and a possible early predictor of clinical severity (B).
- Gastrointestinal, respiratory, and musculoskeletal symptoms are similar in prevalence to other DEEs with hypotonia and sleep disturbances more prominent but movement disorders possibly less prominent (B, C).
- Seizures, developmental delay including communication, sleep and gastrointestinal problems have been expressed as of major concern by caregivers of individuals with CDD.
- More than 200 individual genetic variants and only a small number of recurrent variants have been identified in individuals with CDD. Truncations occur throughout the gene but missense variants only in the kinase domain (C).
- There is some evidence to demonstrate that those with late truncating mutations have better functional ability (C).

What is not known and therefore needed

- Data on the evolution of electroclinical (EEG, evoked potentials) features which may be used for future development of biomarkers (B).
- Seizures are so frequent that accurate counting may be problematic; each seizure event may include distinct semiologies. Therefore, developing assessments that measure the impact of seizures on daily functions is needed (B, C).
- Evaluation of the nature and magnitude of sleep disturbances given their likely burden on the child and family (B, C).

¹ Data informing our clinical knowledge of CDD has been derived to date from four sources: A) case reports and case series; B) a multi-centre clinic-based infrastructure; C) an international caregiver-report database; and D) clinical trials

- Investigation of the prevalence and clinical features of movement disorders, musculoskeletal issues and other comorbidities not yet characterised e.g., behavioural profile, cardiac rhythm abnormalities (B, C).
- Better understanding of the factors that predict phenotypic variability by pooling or harmonising data from multiple sources where practicable (B, C).
- Data on natural history and mortality including the rate of Sudden Unexpected Death from Epilepsy (B, C).

Clinical Management

What is currently known

- Minimal published research on efficacy of ASMs although several drugs in various stages of development
 (D).
- Polypharmacy is common but associated with negative impact on child quality of life (C).
- Purified CBD was associated with some improvement in seizure control in a small open-label study while in an observational study 49 of 70 caregivers expressed benefit from their child's use of a cannabis preparation (C, D).
- Use of ketogenic diet has been shown to provide some short term benefit for seizure control and has been recommended as an initial treatment of infantile spasms along with conventional first line treatment or if first line treatment failed (B, C).
- Improvements in seizure frequency, duration and intensity reported with VNS but no concomitant reduction in ASMs (B, C).
- Absence of research evaluating the impact of therapy on child development.

What is needed

- Replication of small studies showing benefit for particular ASMs initially through large scale observational studies accounting for age, seizure type and combinations of treatment used (B, C).
- Disease-specific clinical trials of new ASMs which like fenfluramine have shown efficacy in other disorders (D).
- Research to evaluate the impact of different therapy approaches on developmental progress (B, C).
- Pre-clinical research to identify potential disease-modifying treatments which go beyond only seizure control. Clinical assessments and biomarkers that are translatable from animal models to a human CDD population are also needed (B, C).
- Program of clinical trial readiness to ensure there are validated outcome measures available for the specific domains (including for quality of life) likely to be involved (B, C)

Advantages and disadvantages of different data sources

- A) Case reports and small series provide in-depth clinical information about a limited number of patients but often cannot stratify their findings by gender or age group and rarely by genotype. Moreover, these patients may not necessarily be representative of the underlying population of CDD cases.
- B) Multicentre clinical studies have the advantage of aggregating data from multiple sites thereby building numbers while still retaining clinical detail. These can take the form of data collected in routine clinical care through the US Centers of Excellence (COE) or in a research infrastructure such as the US Natural History Study (NHS) which since 2013 has undertaken annual clinical evaluations on 72 individuals with CDD. These include structured clinical examinations, parent report, electrophysiological biomarkers and biobanking. Although there are many potential benefits from such a natural history study, disadvantages include cost, sustainability, geographical restrictions, and burden on families. Setting up both types of systems (COE and NHS) requires considerable time, funding and resources especially with respect to the ethical and governance requirements. Families attending such clinics may be more advantaged and again not necessarily representative of the underlying population.
- C) The ICDD is an international database established in 2012 in order to accrue numbers of cases not feasible from an individual country. Data on close to 400 individuals from over 50 countries has now been submitted. Although possibly representative of the children diagnosed in these countries these cases are not necessarily representative of all children with the disorder as diagnosis is a function of access to genetic testing which varies by country and socioeconomic circumstances. The advantages of this database are the much larger numbers. The disadvantages are that data are parent-reported so that certain clinical items are not available.
- D) Given the use of rigorous protocols and validated outcome measures clinical trials can provide best evidence of efficacy for new treatments but their implementation provides many challenges especially for an ultra-rare disorder. Clinical trials in CDD have the advantages of in-person clinician performed assessments, however the assessments are specifically tailored around the interventional end-points of the study, such as seizures. Access to data sets may be limited and available only after publication which often takes considerable time although ClinicalTrials.gov can be a helpful tool in determining the status of a specific trial.

Supplementary Table 1. Functional abilities and comorbidities in the CDKL5 Deficiency Disorder.

	Bahi-B 2008 ¹²		et al	Fehr 6	et al 201	L 6 ³⁰		Mangatt et al Fehr et al 2016 ¹⁷ 2016 ¹⁸							I	Liang 6	Amin et al Liang et al 2019 ³⁹ 2017 ³⁸						yashi et 9¥	al	Brock et al ³³ 2021	Olson et al 2021 ²⁶ ^	Siri et al 2021 ²⁰
Data Ascertain	ment																										
Sample Size (n)		20			124		124-141 172					172 44					170		92			29		48	26	50	
Data Source	Participants referred to central French diagnostic laboratory		ICDD		ICDD		ICDD		CDKL5-UK Charity Database		Systematic review of published cases in the literature			Cohort from CDKL5 Centers of Excellence			Un	kohama iversity Yamaga Jniversi	and ta	Cohort from CDKL5 Centres of Excellence	Cohort from Boston CDKL5 Center of Excellence	Narrative review (n=45) and Pavia, Italy (n=5)					
	F	М	Total	F	F M Total		F M Total		F M Total		F M Total		F M Total		F M Total		F M		Total	Total	Total	Male					
Demographics																											
Median age (yrs)	4.5	-	4.5	6	5.25	6	5.9	5.8	5.9	Τ-	-	5.1	T -	-	5	6.75*	5.2*	6.5*	5	4.8	5	6.0	8.5	-			4
Male freq	_	0%	-	-	13%	-	-	14%	-	-	13%	-	-	11%	-	-	18%	-	-	20%	-	-	28%	-			100%
Original diagnosis										İ																	
EoEE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48%	74%	53%	-	-	-	-	-	-	-	-	-
Atypical RTT	35%#	-	35%#	-	-	-	-	-	-	-	-	-	-	-	-	30%	3%	25%	-	-	-	-	-	-	-	-	-
NSEE	40%#	-	40%#	-	-	-	-	-	-	-	-	-	-	-	-	2%	0%	1%	-	-	-	-	-	-	-	-	-
West	25%#	-	25%#	-	-	-	-	-	-	-	-	-	-	-	-	20%	23%	20%	-	-	-	-	-	-	-	-	-
syndrome/ISSX																											
Functional Abi	lities			l	l									l	I		1	l			l						
Gross Motor																											
Sitting (floor 10 s)										I																	
Independent	-	-	-	67%	37%	61%	-	_	-	-	-	-	-	-	-	-	-	-	-	-	-	15%	0%	10%	-	-	10%
Assisted	-	-	-	9%	7%	9%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2%
Unable	-	-	-	24%	67%	29%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88%
Standing for 20 s																											
Independent	-	-	-	25%	7%	22%	-	-	-	-	-	23%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Assisted	-	-	-	23%	13%	23%	-	-	-	-	-	24%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unable	-	-	-	53%	80%	56%	-	-	-	-	-	53%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transition sit to																											
stand Independent			_	21%	7%	19%	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_			
Assisted	_	_	_	21%	20%	21%		_	_	_	_	_		_	_	_	_]	_	_	_	_	_	_	-	_	
Unable	_	_	_	58%	73%	56%	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	
Walking				3070	7070	30,0				1																	
Independent	-	-	-	22%	7%	20%	-	_	-	-	-	22%	-	-	18%	-	-	-	-	-	-	10%	0%	7%	-	-	5%
Assisted	-	-	-	14%	0%	13%	-	-	-	-	-	15%	-	-	27%	-	-	-	-	-	-	-	-	-	-	-	3%
Unable	-	-	-	64%	93%	68%	-	-	-	-	-	63%	-	-	55%	-	-	-	-	-	-	-	-	-	-	-	92%
Running			-																								
Independent	-	-	-	13%	8%	13%	-	-	-	-	-	-	-	-	19%	-	-	-	-	-	-	-	-	-	-	-	-
Assisted	-	-	-	5%	0%	4%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unable	-	-	-	82%	92%	83%	_	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fine Motor Hand function													1						I			-					
rianu iunction																											
	-	-	-	40%	13%	36%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

	1	1	1	1			1	1	1	1 1		1	1 1		ı — — —		1	1		1		1		1	ı	1	
Can grasp small																											
object	-	-	-	26%	13%	24%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Can grasp large																											
object	-	-	-	34%	75%	41%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70%	88%	72%	-	-	
Unable to grasp																											
Stereotypies	85%#	-	85%#	-	_	-	-	_	-	-	_	-	l	_	-	83%#	40%#	75%#				38%	13%	28%	_	_	_
Communication			0070	I	1	1	I		I			1			l .	3370	.070	7.575	1			50,0	2070	2070			
Spoken language,	_	-	-	26%	0%	23%	_	_	_	Ι - Ι	_	19%	T - T	_	_	_	-	_	-	_	_	-	-	_	_	-	-
signs and abstract																											
symbols																											
Complex	_	_	_	39%	25%	37%	_	_	_	_	_	52%	_	_	_	_	_	_	_	_	_	_	_	_		_	_
	_	_	_	35/0	23/0	37/0	_	_	_	-	_	32/0	- 1	-	_	_	-	-	-	_	_	-	_	_	-	_	-
gesturing,																											
symbols and/or				250/	750/	100/						200/															
vocalisations	-	-	-	35%	75%	40%	-	-	-	-	-	29%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Simple																											
communication																											
Seizures																											
Initial seizure type																											
Focal	-	-	-	-	-	-	-	_	-	_	-	-	-	-	-	-	-	-	23%	17%	22%	52%	25%	45%	-	_	38%
Tonic	_	_	_	_	-	_	-	_	_	_	_	-	-	_	_	-	_	_	34%	22%	32%	19%	38%	24%	_	_	22%
Spasms	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	19%	39%	23%	19%	13%	17%	_	_	36%
GTC	_	_	_	_	_	_	_	_	_	_	_	_		_	_	_	_	_	24%	11%	22%	10%	25%	14%	_	_	2%
					-	-			_		_		- 1	-		_		_	5%	11%	7%	0%	25%		_	_	2%
Myoclonic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-						7%	_	-	
Clonic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9%	6%	9%	-	-	-	-	-	4%
HTSS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11%	6%	10%	-	-	-	-	-	-
Seizure types										1																	
Epileptic spasms		_		_								_			_		_		82%	78%	82%		_				76%
	-		_		-	_	-	_	_	-	-		- 1	-		-		-		61%		_		_	_	-	
Tonic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65%		64%	-	-	-	_	-	53%
HTSS combined	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	58%	50%	57%	-	-	-	-	-	-
HTSS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26%	17%	24%	-	-	-	-	-	-
HTSS-like	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32%	39%	34%	-	-	-	-	-	-
GTC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39%	11%	34%	-	-	-	-	-	20%
Myoclonic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41%	33%	39%	-	-	-	-	-	33%
Clonic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9%	17%	11%	-	-	-	-	-	
Atonic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11%	0%	9%	-	-	-	-	-	6%
Absence	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3%	0%	2%	-	-	-	-	-	4%
Focality	-	-	-	-	-	-	-	_	-	-	-	-	_	-	-	-	-	-	30%	33%	30%	-	-	-	-	65%	31%
Hypsarrhythmia	-	-	-	-	-	-	-	-	-	-	-	-	- 1	-	-	23%	48%	29%	34%	56%	38%	62%	75%	66%		39%	-
Seizure free	30%	-	30%	-	-	-	_	_	_	† <u>-</u>	_	44%	_	_	7%	-	-	-	42%	50%	43%	19%	0%	14%	_	-	-
periods ever	55/0		23/0									,			','				/ 0	33/0	.5/0		270	- 1/0			
(honeymoon																											
period)																											
Other Comorb	iditias					<u> </u>																					
Vision/Neurolog																											
	icui					1	1			1			1		l		1	1	770/	720/	760/				02.50/	1000/	
Cortical visual	_	-	-	_	-	-	-	-	_	-	-	-	-	-	-				77%	72%	76%	-	-	-	93.5%	100%	-
impairment	l			1			l	1	l													l					

II and a de	050/#	l	050/#		1	1	1	ı					1		I	050/#	040/#	020/#	I	1		1			I		I
Hypotonia	85%#	-	85%#	-	-	-	-	-	-	-	-	-	-	-	-	95%#	81%#	92%#	-	-	-	-	-	-			-
Brain MRI																	#										
Normal	4%#	-	4%#	-	-	-	-	-	-	-	-	-	-	-	-	74%#	47%#	69%#	-	-	-	62%	25%	52%	-	-	-
Brain atrophy	65%#	-	65%#	-	-	-	-	-	-	-	-	-	-	-	-	26%#	53%#	31%#	-	-	-	33%	75%	45%	-	-	-
Other	31%#	-	31%#	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
abnormality																											
Gastrointestina																											
Any	72%	-	72%	-	-	-	86%	89%	87%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Constipation	-	-	-	-	-	-	69%	83%	71%	-	-	-	-	-	48%	-	-	-	-	-	-	-	-	-	-	-	-
Reflux				-	-	-	65%	59%	64%	-	-	-	-	-	22%	-	-	-	-	-	-	-	-	-	-	-	-
Air swallowing	15%	-	15%	-	-	-	28%	24%	27%	-	-	-	-	-	40%	-	-	-	-	-	-	-	-	-	-	-	-
Gastrostomy ever	-	-	-	-	-	-	24%	58%	29%	-	-	-	-	-	31%	-	-	-	-	-	-	-	-	-	-	-	-
Sleep																											
Any	55%	-	55%	-	-	-	86%	94%	87%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Night waking	-	-	-	-	-	-	59%	53%	59%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Daytime napping	-	-	-	-	-	-	47%	44%	47%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bruxism	40%	-	40%	-	-	-	38%	50%	40%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Night screaming	-	-	-	-	-	-	23%	22%	23%	-	-	-	-	ı	-	-	-	-	-	-	-	-	-	-	-	-	-
Night laughing	-	-	-	-	-	-	26%	33%	27%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory																											
Any	-	-	-	-	-	-	30%	50%	33%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hyperventilation	15%	-	15%	-	-	-	14%	13%	13%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Apnoea/breath	-	-	-	-	-	-	24%	44%	26%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
holding																											
Pneumonia ever	-	-	-	-	-	-	17%	53%	21%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Aspiration ever	-	-	-	-	-	-	18%	53%	23%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skeletal																											
Scoliosis	-	-	-	-	-	-	19%	31%	20%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cardiovascular			•		•		•								•					•							
Arrythmia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38%	-	-	-	-	-	-	-	-	-	-	-	-
	1				٠.	1							٠				0					_			٠		

N.B. percentages are rounded to nearest percent, * Average age used instead of median age, # Liang et al.³⁹ study consists of an aggregation of case reports and case series reported in the literature and contains the subset of individuals from the Bahi-Buisson et al. study¹², ^Age at diagnosis of visual impairment was 2 years and above. ^Ψ Please note, individuals may be coded/diagnosed with more than one seizure type hence the total percentage for initial seizure types and seizure types may not add up to 100%. Additionally, not all publications used the same seizure classifications systems. The authors attempted to align all classifications with the most recent ILAE classification.

Abbreviations: ICDD, International CDKL5 Disorder Database; F, female; M, male; freq, frequency; EoEE, early-onset epileptic encephalopathy; RTT, Rett syndrome; NSEE, nonspecific epileptic encephalopathy; ISSX, X-linked infantile spasms; HTSS, hypermotor-tonic-spasms sequence; GTC, generalized tonic-clonic;

Supplementary Table 2. Quality of Life Inventory-Disability (QI- Disability): Domains and Related Questions.¹


Domains of QI- Disability	No of items	Questions
Physical health	4	Over the past month, how often has your child
,		Had enough energy to participate in routines and activities.
		Kept in good general health (e.g., avoided coughs, colds, fever).
		Slept well during the night.
		Been alert and aware during the day.
Positive emotion	4	Over the past month, how often has your child
		Been in a good mood.
		Smiled or brightened their facial expression.
		Showed happiness through body language (e.g., making eye contact, body facing
		others).
		Showed cheeky or comical mannerisms (e.g., laughed, giggled).
Negative	7	Over the past month, how often has your child
emotion	'	Been unsettled without an apparent reason.
Ciliotion		Showed aggression (e.g., hitting, kicking, using offensive language, being
		destructive).
		Appeared upset or angry (e.g., crying, screaming, moving, or stiffening the body).
		Become withdrawn with a low mood.
		Deliberately hurt themselves.
		Expressed discomfort with changes in routine (e.g., carers, school, out-of-home
		care).
		Showed signs of being anxious or agitated (e.g., teeth grinding, fast breathing,
		avoidance).
Social interaction	7	Over the past month, how often has your child
30Clai iiiteraction	'	Expressed happiness when they were understood.
		Appeared relaxed when making eye contact.
		Initiated greetings with people verbally or nonverbally (e.g., eye contact). Enjoyed being included.
		Enjoyed the social experiences of meal times. Responded positively when others paid attention to them (e.g., your child smiled,
		showed interest).
		Showed pleasure or excitement when looking forward to activities (e.g., going to
Leisure and the	5	school, outings, events). Over the past month, how often has your child
	3	
outdoors		Enjoyed moving their body (e.g., walking, swinging, swimming).
		Enjoyed feeling steady or stable during physical activities (e.g., sitting, standing, bike
		riding).
		Enjoyed physical activities (e.g., going out for a walk, swimming, swinging, dancing).
		Enjoyed going on outings in the community (e.g., shopping, party, sports, theatre).
Indonondonos	-	Enjoyed spending time outdoors (e.g., contact with water, grass, wind, sunshine).
Independence	5	Over the past month, how often has your child
		Expressed their needs (e.g., hunger, thirst, toileting).
		Made their own choices for activities or things they enjoy (e.g., DVD's, toys).
		Helped to complete routine activities (e.g., dressing, feeding, chores around the
		house).
		Enjoyed making things with their hands—can be with help (e.g., building blocks,
		painting, cooking).
	l	Enjoyed using technology (e.g., computer, tablet, applications on phones)

^{1.} Downs J, Jacoby P, Leonard H, Epstein A, Murphy N, Davis E, Reddihough D, Whitehouse A, Williams K. Psychometric properties of the Quality of Life Inventory-Disability (QI-Disability) measure. *Qual Life Res* 2019; **28**: 783-94

Supplementary Table 3. Preclinical outcome measures from preclinical trials and corresponding potential clinical outcome measures.

Preclinical				Preclinic	al Outcome	Measure	S		
Trial	Hindlimb clasping	Rotorod	Repetitive behaviour	Learning and memory	Hyperactivity	Breathing pattern	Visual responses	Socialization	Seizure latency
GSK3b inhibitor ⁸²	×	×	×	✓	×	×	×	×	×
Protein replacement ⁸³	✓	×	✓	✓	✓	✓	✓	×	×
Memantine ⁸⁴	×	×	✓	✓	×	×	×	✓	×
IEM 14606 ⁸⁵	×	×	×	✓	×	×	×	✓	✓
Sertraline ⁸⁶	×	×	✓	✓	✓	×	×	×	×
Gene replacement ⁸⁷	✓	✓	✓	✓	✓	×	×	×	×
Green tea ⁸⁸	✓	×	✓	✓	×	×	×	×	×
Potential Clinical Outcome	Hindlimb clasping	Rotorod	Repetitive behaviour	Learning and memory	Hyperactivity	Breathing pattern	Visual responses	Socialization	Seizure latency
Measures									
CCSA	✓	✓	✓	✓	✓	✓	×	✓	×
CSBS-DP	×	×	×	✓	×	×	×	×	×
QI-Disability	×	×	*	✓	*	×	×	✓	×
VEP	×	×	×	×	×	×	✓	×	×
Resting state EEG	×	×	×	×	×	×	×	×	✓

Supplementary Figure 1: Total Quality of Life (QOL) scores in children with CDKL5 Deficiency Disorder¹ and other Intellectual Disabilities (Autism Spectrum Disorder, Cerebral Palsy, Down syndrome, Rett syndrome).²



- 1. Leonard H, Junaid M, Wong K, Demarest S, Downs J. Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder. Epilepsy Res. 2021;169:106521.
- 2. Williams K, Jacoby P, Whitehouse A, Kim R, Epstein A, Murphy N, et al. Functioning, participation, and quality of life in children with intellectual disability: an observational study. Dev Med Child Neurol. 2021;63(1):89-96.

Supplementary Figure 2: A framework of likely observations contributing to the diagnosis of CDKL5 Deficiency Disorder.

Early onset epilepsy

Abnormal tone and impaired development

Gene panel testing for definitive diagnosis

Natural history of CDD

Fehr et al. Eur J Hum Genet 2013; 21(3): 266-73.

Clinical features CDD <3m

- Median onset of epilepsy 6 weeks
- Early focal seizures and/or spasms
- EEG can be normal or mildly abnormal
- Other features including prominent hypotonia, delay in early developmental milestones

Clinical features CDD 3m to 2y

- Onset of seizures by 1 year in 90%
- Refractory seizures, may have honeymoon period
- EEG background is progressively abnormal
- May overlap with West syndrome
- · Continued hypotonia
- Severe developmental delay and CVI +/- periods of regression
- Comorbidities such as sleep or gastrointestinal dysfunction

Clinical features CDD childhood/adulthood

- Refractory seizures
- May overlap with Lennox Gastaut syndrome
- Severe cognitive & motor impairments
- May have experienced regression with or without exacerbation of seizures
- Comorbidities such as sleep or gastrointestinal dysfunction

20 commonest genes (dominant (blue) and X-linked (black) implicated on four or more occasions from 24 NGS studies in epilepsy.

Symonds, A. McTague / European Journal of Paediatric Neurology 24 (2020) 1.5e.23

SCN1A, KCNQ2, CDKL5, SCN2A, STXBP1, PCDH19, PRRT2, SCN8A, MECP2, SLC2A1, UBE3A, TSC2, GABRG2, GRIN2A, KCNT1, FOXG1, TPP1, GABRB3, ARX, GABRA1

Most common neonatal/early infantile onset DEEs with similarity to CDD: KCNQ2, SCN2A, STXBP1 but more likely to be associated with burst suppression/Ohtahara syndrome

Distinguished from other Rettrelated DEEs by genetic mutation, age of epilepsy onset and other specific features

Cutri-French et al 2020 doi.org/10.1002/ana. 25797

Marafi D, et al. Neurology. 2019;92(2):e108-e14.

Rett syndrome (MECP2)

Median age of seizure onset 4 year Developmental regression & hand stereotypies Mainly females Autonomic dysfunction and sleep dysfunction

FOXG1

Onset of epilepsy later than in CDD but earlier than in RTT Abnormal neuroimaging Movement disorder with choreadystonia CVI

MECP2 Duplication Disorder

Median age of seizure onset 9 year Refractory seizures, often consistent with Lennox Gastaut syndrome Frequent respiratory infections Mainly males, autism, dysmorphic facies